ClinicalTrials.gg
Active, not recruitingNCT06325566HyaluronicAcidUpdated Jun 17, 2026

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

A Phase 3 interventional study of Rexlemestrocel-L + HA mixture and Saline in Degenerative Disc Disease, sponsored by Mesoblast, Ltd.. Active, not recruiting at 40 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Mesoblast, Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 60 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.

Planned enrollment
16th of 141
300 · median 57
Started
2024
with 9 others
Phase 3
16 of 232
3 open now
Primary completion
2027-07
later than 37 of 59 live
Registered
211th of 232
by date
Lead sponsor
6 of 232
Mesoblast, Ltd.

Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 16th largest by planned enrollment of the 141 interventional ones that give a count, is one of 10 that started in 2024, is one of 16 in phase 3, reaches primary completion later than 37 of the 59 other live ones, and was the 211th registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Intervertebral Disc Degeneration with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control through 12 months post-treatment.

03

Conditions studied

  • Degenerative Disc Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with moderate to severe low back pain for a duration of at least six months who have failed at least 3 months of conservative care.
  • Participants who have moderate radiographic degeneration of an intervertebral disc from L1 to S1, with a single disc suspected of causing chronic lower back pain (CLBP).

Exclusion criteria

Exclusion Criteria:

  • Participants who have been a recipient of prior allogeneic stem cell/progenitor cell therapy for any indication or autologous stem cell/progenitor cell therapy or other biological intervention to repair the index intervertebral disc.
  • Participants with low back pain duration of less than 6 months or greater than 60 months.
  • Participants who have not received at least 3 months of conservative treatment for back pain without adequate pain relief.
  • Participants taking systemic .
  • Participants with osteoporosis.
  • Participants with alcohol or substance abuse problems.
  • Participants with severe depression or anxiety.
  • Participants with cauda equina syndrome; fibromyalgia, symptomatic central vertebral canal stenosis, lumbar spondylitis or other undifferentiated spondyloarthropathy affecting the index disc.
  • Participants having undergone a surgical procedure affecting the structure/biomechanics of the disc (e.g., discectomy, intradiscal electrothermal therapy, intradiscal radiofrequency, artificial disc replacement, interbody fusion, laminectomy, etc.) at the index or adjacent levels.
  • Participants who have received any lumbar intradiscal injection into the index disc or adjacent discs within three months prior to the start of screening, other than injection of contrast medium for discography.
  • Participants who received an epidural injection within 6 weeks prior to .
  • Participants with evidence of neurologic deficit on any component of the lumbar neurological exam at baseline.
  • Participants with sacroiliac (SI) joint pain, as determined by a targeted physical exam, or SI joint injection.
  • Participants with facet joint pain, as determined by a medial branch block.
  • Participants with more than a single painful level.
  • Participants with a full thickness annular tear observed on magnetic resonance imaging (MRI) or discography.
  • Participants with low back pain that is less than moderate in severity.
  • Participants with extreme low back pain.
  • Participants who lack moderate to extreme functional limitations/disability.

Note: Other exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Rexlemestrocel-L + HA

    Participants will receive rexlemestrocel-L 2.0 mL injection of approximately 6 million rexlemestrocel-L cells in freeze media mixed in a 1:1 by-volume ratio with hyaluronic acid (HA) solution on Day 0.

    Drug: Rexlemestrocel-L + HA mixture

  • Sham comparator
    Control Group

    Participants will receive saline solution as a sham procedure to simulate the active treatment injection on Day 0.

    Drug: Saline

Interventions

  • DrugRexlemestrocel-L + HA mixture

    Rexlemestrocel-L will be combined in 1:1 by-volume ratio with HA solution and the resulting mixture will be administered as intradiscal injection.

  • DrugSaline

    Saline solution injection adjacent to the index disc.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Daily Average Low Back Pain at 12 Months Post-treatment Based on Visual Analog Scale (VAS) Score

    Low back pain intensity will be measured using a VAS ranging from 0-100 millimeter (mm). A score of 0 represents no pain and 100 represents worst possible pain.

    Time frame: Baseline and Month 12

  2. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to Month 24

Secondary outcomes

  1. Percentage of 30% VAS Pain Responders at 12 Months Post-treatment

    Responders are defined as participants who have at least a 30% decrease from baseline in daily average low back pain VAS score (measured as the average VAS score over 7 days). VAS score ranges from 0 (no pain) to 100 (worst possible pain).

    Time frame: Month 12

  2. Mean Change From Baseline in Quality of Life Measured by Euroqol-5D (EQ-5D) Index Score at 12 Months Post-treatment

    The EQ-5D is a generic instrument that consists of 5 dimensions: Mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression, rated over five levels of severity ranging from no issues to extreme issues and the responses can be converted into a single number called an index score. The index scores are calculated ranging from 0 (worst quality of life) to 1 (perfect quality of life).

    Time frame: Baseline and Month 12

  3. Percentage of Minimal Pain Responders at 12 Months Post-treatment

    Minimal pain responders are defined as participants who have a low back pain daily average VAS score (measured as the average VAS score over 7 days) of 20 mm or less. VAS score ranges from 0 (no pain) to 100 (worst possible pain).

    Time frame: Month 12

  4. Mean Change From Baseline in Function as Measured by Oswestry Disability Index (ODI) Questionnaire Score at 12 Months Post-treatment

    ODI scores ten aspects of the participant's home and work life and analgesic use in a range of 0 (least amount of disability) to 5 (severe disability). The disability index is then calculated by summing the scores for all questions answered, then multiplied by two and reported in a 0 to 100% range where higher numbers indicate a higher level of disability.

    Time frame: Baseline and Month 12

  5. Percentage of Participants With 30% VAS and 10-point ODI Treatment Success at 12 Months Post-treatment

    Treatment success based on the percentage of participants who have at least a 30% reduction from baseline in daily average low back pain VAS score (measured as the average VAS score over 7 days) with at least a 10-point decrease from baseline ODI score will be reported.

    Time frame: Month 12

  6. Percentage of Participants Who Ceased Opioid Usage at 24 Months Post-treatment

    Time frame: Month 24

07

Study locations

40 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jul 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2024
First posted
Mar 22, 2024
StartActual
Jul 3, 2024
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2028
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06325566
Lead sponsor
Mesoblast, Ltd.
Responsible party
Sponsor
First posted
Mar 22, 2024
Start date
Jul 3, 2024
Primary completion
Jul 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Jun 17, 2026

Study contacts

Roger D Brown
study director · Mesoblast, Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion